-
公开(公告)号：US20060135428A1
公开(公告)日：2006-06-22
申请号：US11350703
申请日：2006-02-08
CPC分类号： C07K14/005 , A61K38/00 , C07K14/605 , C12N2740/16122
摘要： Modified anti-angiogenic peptides are disclosed. The modified peptides are capable of forming a peptidase stabilized anti-angiogenic peptide. The modified anti-angiogenic peptides, particularly modified kringle 5 peptides are capable of forming a conjugate with a blood protein. Conjugates are prepared from anti-angiogenic peptides, particularly kringle 5 peptides, by combining the peptide with a reactive functional group with a blood protein. The conjugates may be formed in vivo or ex vivo. The conjugates are administered to patients to provide an anti-angiogenic effect.
-
22.发明申请Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders 失效持久的胰高血糖素样肽2（GLP-2）用于治疗胃肠道疾病和病症公开(公告)号：US20060217304A1
公开(公告)日：2006-09-28
申请号：US11318323
申请日：2005-12-23
申请人： Dominique Bridon , Nissab Boudjellab , Roger Leger , Martin Robitaille , Karen Thibaudeau , Julie Carette
发明人： Dominique Bridon , Nissab Boudjellab , Roger Leger , Martin Robitaille , Karen Thibaudeau , Julie Carette
IPC分类号： A61K38/26 , C07K14/605
CPC分类号： C07K14/605 , A61K38/26 , A61K38/38 , A61K47/643 , C07K2319/00 , A61K2300/00
摘要： This invention relates to glucagon-like peptide 2 (GLP-2) derivatives. In particular, this invention relates to GLP-2 peptide derivatives having an extended in vivo half-life, for the treatment or prevention of gastrointestinal disorders or diseases such as inflammatory bowel disease and other gastrointestinal functions, from any segment of the gastrointestinal tract, from the oesophagus to the anus.
摘要翻译： 本发明涉及胰高血糖素样肽2（GLP-2）衍生物。 特别地，本发明涉及具有延长的体内半衰期的GLP-2肽衍生物，用于治疗或预防胃肠道疾病或疾病如炎症性肠病和其他胃肠功能，从胃肠道的任何部分，从 食道到肛门。
-
23.发明申请Method of treatment of diabetes and/or obesity with reduced nausea side effect 失效减少恶心副作用的糖尿病和/或肥胖症的治疗方法公开(公告)号：US20070207958A1
公开(公告)日：2007-09-06
申请号：US11595576
申请日：2006-11-09
IPC分类号： A61K38/22
CPC分类号： A61K38/26 , A61K47/643
摘要： The present invention provides methods of administering an insulinotropic peptide in an amount effective to treat a disorder or condition while reducing nausea side effect by administering to a subject in need thereof an insulinotropic peptide conjugated to albumin. The present invention also provides methods of selecting a subject for administration of a conjugated insulinotropic peptide. Exemplary disorders or conditions treatable with an insulinotropic peptide include obesity and type II diabetes.
摘要翻译： 本发明提供以有效治疗病症或病症的量施用促胰岛素肽的方法，同时通过向有需要的受试者施用与白蛋白缀合的促胰岛素肽来减轻恶心副作用。 本发明还提供了选择用于给予共轭促胰岛素肽的受试者的方法。 用促胰岛素肽治疗的示例性疾病或病症包括肥胖症和II型糖尿病。
-
公开(公告)号：US20050187159A1
公开(公告)日：2005-08-25
申请号：US11066697
申请日：2005-02-25
申请人： Dominique Bridon , Alan Ezrin , Peter Milner , Darren Holmes , Karen Thibaudeau
发明人： Dominique Bridon , Alan Ezrin , Peter Milner , Darren Holmes , Karen Thibaudeau
CPC分类号： C07K19/00
摘要： A method for protecting a peptide from peptidase activity in vivo, the peptide being composed of between 2 and 50 amino acids and having a C-terminus and an N-terminus and a C-terminus amino acid and an N-terminus amino acid is described. In the first step of the method, the peptide is modified by attaching a reactive group to the C-terminus amino acid, to the N-terminus amino acid, or to an amino acid located between the N-terminus and the C-terminus, such that the modified peptide is capable of forming a covalent bond in vivo with a reactive functionality on a blood component. In the next step, a covalent bond is formed between the reactive group and a reactive functionality on a blood component to form a peptide-blood component conjugate, thereby protecting said peptide from peptidase activity. The final step of the method involves the analyzing of the stability of the peptide-blood component conjugate to assess the protection of the peptide from peptidase activity.
-
-
-
搜索结果
24 条记录 (耗时 0.032 秒)
